Joshua Fitch, Senior Editor

The primary outcome was an elevated HbA1c level greater than or equal to 5.7% (prediabetes or undiagnosed presumed T2D).

pJIA can lead to an increased risk of permanent joint damage as well as delayed growth and development.

Overall, the findings of the study support the clinical utility of combining trio-WES sequencing with CNV-seq in the etiologic diagnosis and management of early-childhood GDD.

Once-daily, steroid-free, topical roflumilast cream 0.15% has a PDUFA date of July 7, 2024.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The 2-drug, fixed-dose combination tablet contains darunavir, an HIV-1 protease inhibitor, and cobicistat, a CYP3A inhibitor that serves as a PK enhancer or “booster.”

Over the winter, the omicron JN.1 lineages overtook XBB strains as dominant.

Though some drowning prevention strategies seem common or routine, data demonstrate drowning deaths among children have risen in recent years, which should prompt conversations with families on refreshers and new prevention initiatives.

Additionally, a new weight-based oral solution, RINVOQ LQ, is now available as an option for the pediatric populations.

Management of ICEP with monoclonal antibodies against IL-5 and IgE (omalizumab) could be promising according to study authors, though extent of evidence is lacking.

Mesoblast Limited's chief executive announced a BLA resubmission for remestemcel-L is expected to be filed with the FDA this quarter.

The maximum daily dose has increased from 80 mg to 100 mg.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The disorders can impact the academic and social functioning of college students and have been associated with long-term health issues.

Prior to the federal agency's decision, children aged 5 years and older could only receive belimumab through an intravenous (IV) formulation.

The therapy was previously granted accelerated approval for the thyroid cancer indications in adults and pediatric patients aged 12 years and older.

Analysis demonstrated a significant correlation between elevated levels of serum circulating magnesium and serum vitamin D with increased risk of childhood asthma. 

The once daily extended-release oral suspension with nighttime dosing is approved to treat ADHD as a monotherapy or as an adjunctive therapy to approved CNS stimulant medications.

Peanut consumption starting in infancy resulted in lasting tolerance into adolescence.

Findings indicate that chronically high stress markers could have a role in the development of EF impairments in early adolescents with cCHD.

Wendy Ripple, MD, provides suggestions for sunscreens in the pediatric population.

In the retrospective, population-based cohort study, the investigators used linked administrative health records of all children born in Western Australia between January 1, 2003 and December 31, 2018 (n = 401,462).

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Children with hypertension were at an increased risk of stroke, congestive heart failure, and other major adverse cardiac events compared to non-hypertensive individuals.

As children head outside for summer, providers can remind parents of some staple sun safety tips.

Approximately 40% of patients who receive PN in the United States as an intravenous source of nourishment are under 18 years of age.

Investigators found that higher baseline HbA1c was associated with greater T2D risk.

Even 6 years after publication, the investigative team stated it is unknown if the recommendations have led to changes in primary care.

“We found no statistically significant effect of early iron supplementation on developmental scores at 24 and 36 months,” wrote the study investigators.

The federal agency has accepted the sBLA for Priority Review designation, with a target action date of September 15, 2024.